Bile acids and their effects on diabetes

doi:10.1007/s11684-018-0644-x

Frontiers of Medicine

2018, Vol. 12

Issue (6): 608-623 https://doi.org/10.1007/s11684-018-0644-x

本期目录

Bile acids and their effects on diabetes

Cynthia Rajani¹, Wei Jia^1,²(

)

¹. University of Hawaii Cancer Center, Honolulu, HI 96813, USA
². Shanghai Key Laboratory of Diabetes Mellitus and Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China

全文: PDF(661 KB) HTML

Abstract：

Diabetes is a widespread, rapidly increasing metabolic disease that is driven by hyperglycemia. Early glycemic control is of primary importance to avoid vascular complications including development of retinal disorders leading to blindness, end-stage renal disease, and accelerated atherosclerosis with a higher risk of myocardial infarction, stroke and limb amputations. Even after hyperglycemia has been brought under control, “metabolic memory,” a cluster of irreversible metabolic changes that allow diabetes to progress, may persist depending on the duration of hyperglycemia. Manipulation of bile acid (BA) receptors and the BA pool have been shown to be useful in establishing glycemic control in diabetes due to their ability to regulate energy metabolism by binding and activating nuclear transcription factors such as farnesoid X receptor (FXR) in liver and intestine as well as the G-protein coupled receptor, TGR5, in enteroendocrine cells and pancreatic β-cells. The downstream targets of BA activated FXR, FGF15/21, are also important for glucose/insulin homeostasis. In this review we will discuss the effect of BAs on glucose and lipid metabolism and explore recent research on establishing glycemic control in diabetes through the manipulation of BAs and their receptors in the liver, intestine and pancreas, alteration of the enterohepatic circulation, bariatric surgery and alignment of circadian rhythms.

Key words： bile acids metabolic memory diabetes circadian rhythm bariatric surgery

收稿日期: 2017-10-12 出版日期: 2018-12-03

Corresponding Author(s): Wei Jia

引用本文:

. [J]. Frontiers of Medicine, 2018, 12(6): 608-623.
Cynthia Rajani, Wei Jia. Bile acids and their effects on diabetes. Front. Med., 2018, 12(6): 608-623.

链接本文:

https://academic.hep.com.cn/fmd/CN/10.1007/s11684-018-0644-x
https://academic.hep.com.cn/fmd/CN/Y2018/V12/I6/608

Fig.1

Fig.2

Fig.3

Tab.1

Tab.2

Fig.4

Fig.5

1	Abramowicz M, Zuccotti G. Drugs for diabetes. Treat Guidel Med Lett 2005; 3(36): 57–62 pmid: 16012392
2	Ceriello A. The emerging challenge in diabetes: the “metabolic memory”. Vascul Pharmacol 2012; 57(5-6): 133–138 https://doi.org/10.1016/j.vph.2012.05.005 pmid: 22609133
3	Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, Boemi M, Giugliano D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008; 57(5): 1349–1354 https://doi.org/10.2337/db08-0063 pmid: 18299315
4	Ceriello A, Esposito K, Ihnat M, Thorpe J, Giugliano D. Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes. J Clin Endocrinol Metab 2009; 94(8): 2751–2756 https://doi.org/10.1210/jc.2009-0762 pmid: 19491221
5	Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643–2653 https://doi.org/10.1056/NEJMoa052187 pmid: 16371630
6	Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(6865): 813–820 https://doi.org/10.1038/414813a pmid: 11742414
7	Foufelle F, Ferré P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002; 366(Pt 2): 377–391 https://doi.org/10.1042/bj20020430 pmid: 12061893
8	Banerjee PS, Lagerlöf O, Hart GW. Roles of O-GlcNAc in chronic diseases of aging. Mol Aspects Med 2016; 51: 1–15 https://doi.org/10.1016/j.mam.2016.05.005 pmid: 27259471
9	Hanssen NM, Beulens JW, van Dieren S, Scheijen JL, van der A DL, Spijkerman AM, van der Schouw YT, Stehouwer CD, Schalkwijk CG. Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL). Diabetes 2015; 64(1): 257–265 https://doi.org/10.2337/db13-1864 pmid: 24848072
10	Guinez C, Filhoulaud G, Rayah-Benhamed F, Marmier S, Dubuquoy C, Dentin R, Moldes M, Burnol AF, Yang X, Lefebvre T, Girard J, Postic C. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes 2011; 60(5): 1399–1413 https://doi.org/10.2337/db10-0452 pmid: 21471514
11	Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014; 66(4): 948–983 https://doi.org/10.1124/pr.113.008201 pmid: 25073467
12	Kong B, Wang L, Chiang JY, Zhang Y, Klaassen CD, Guo GL. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012; 56(3): 1034–1043 https://doi.org/10.1002/hep.25740 pmid: 22467244
13	Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7(8): 678–693 https://doi.org/10.1038/nrd2619 pmid: 18670431
14	Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev 2003; 83(2): 633–671 https://doi.org/10.1152/physrev.00027.2002 pmid: 12663868
15	Zhang YK, Guo GL, Klaassen CD. Diurnal variations of mouse plasma and hepatic bile acid concentrations as well as expression of biosynthetic enzymes and transporters. PLoS One 2011; 6(2): e16683 https://doi.org/10.1371/journal.pone.0016683 pmid: 21346810
16	Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 2006; 47(2): 241–259 https://doi.org/10.1194/jlr.R500013-JLR200 pmid: 16299351
17	Dawson PA, Lan T, Rao A. Bile acid transporters. J Lipid Res 2009; 50(12): 2340–2357 https://doi.org/10.1194/jlr.R900012-JLR200 pmid: 19498215
18	Meier PJ, Stieger B. Bile salt transporters. Annu Rev Physiol 2002; 64(1): 635–661 https://doi.org/10.1146/annurev.physiol.64.082201.100300 pmid: 11826283
19	Lan T, Morgan DA, Rahmouni K, Sonoda J, Fu X, Burgess SC, Holland WL, Kliewer SA, Mangelsdorf DJ. FGF19, FGF21, and an FGFR1/β-Klotho-activating antibody act on the nervous system to regulate body weight and glycemia. Cell Metab 2017; 26(5): 709–718.e3 https://doi.org/10.1016/j.cmet.2017.09.005 pmid: 28988823
20	Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy. Diabetes 2010; 59(11): 2697–2707 https://doi.org/10.2337/db10-1032 pmid: 20705776
21	Chung ST, Hsia DS, Chacko SK, Rodriguez LM, Haymond MW. Increased gluconeogenesis in youth with newly diagnosed type 2 diabetes. Diabetologia 2015; 58(3): 596–603 https://doi.org/10.1007/s00125-014-3455-x pmid: 25447079
22	Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, Fukamizu A. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004; 279(22): 23158–23165 https://doi.org/10.1074/jbc.M314322200 pmid: 15047713
23	Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56(4): 952–964 https://doi.org/10.1016/j.jhep.2011.08.025 pmid: 22173168
24	Dentin R, Girard J, Postic C. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 2005; 87(1): 81–86 https://doi.org/10.1016/j.biochi.2004.11.008 pmid: 15733741
25	Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003; 38(1): 123–132 https://doi.org/10.1053/jhep.2003.50307 pmid: 12829994
26	Denechaud PD, Dentin R, Girard J, Postic C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett 2008; 582(1): 68–73 https://doi.org/10.1016/j.febslet.2007.07.084 pmid: 17716660
27	Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006; 103(4): 1006–1011 https://doi.org/10.1073/pnas.0506982103 pmid: 16410358
28	Gonzalez FJ, Jiang C, Patterson AD. An Intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology 2016; 151(5): 845–859 https://doi.org/10.1053/j.gastro.2016.08.057 pmid: 27639801
29	Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM, Mauer J, Xu E, Hammerschmidt P, Brönneke HS, Trifunovic A, LoSasso G, Wunderlich FT, Kornfeld JW, Blüher M, Krönke M, Brüning JC. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab 2014; 20(4): 678–686 https://doi.org/10.1016/j.cmet.2014.08.002 pmid: 25295788
30	Jiang C, Xie C, Lv Y, Li J, Krausz KW, Shi J, Brocker CN, Desai D, Amin SG, Bisson WH, Liu Y, Gavrilova O, Patterson AD, Gonzalez FJ. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun 2015; 6(1): 10166 https://doi.org/10.1038/ncomms10166 pmid: 26670557
31	Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 2013; 4(1): 2384 https://doi.org/10.1038/ncomms3384 pmid: 24064762
32	Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011; 331(6024): 1621–1624 https://doi.org/10.1126/science.1198363 pmid: 21436455
33	Stefano GB, Challenger S, Kream RM. Hyperglycemia-associated alterations in cellular signaling and dysregulated mitochondrial bioenergetics in human metabolic disorders. Eur J Nutr 2016; 55(8): 2339–2345 https://doi.org/10.1007/s00394-016-1212-2 pmid: 27084094
34	Whelan SA, Dias WB, Thiruneelakantapillai L, Lane MD, Hart GW. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-linked β-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem 2010; 285(8): 5204–5211 https://doi.org/10.1074/jbc.M109.077818 pmid: 20018868
35	Housley MP, Rodgers JT, Udeshi ND, Kelly TJ, Shabanowitz J, Hunt DF, Puigserver P, Hart GW. O-GlcNAc regulates FoxO activation in response to glucose. J Biol Chem 2008; 283(24): 16283–16292 https://doi.org/10.1074/jbc.M802240200 pmid: 18420577
36	Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, Kusminski CM, Bauer SM, Wade M, Singhal E, Cheng CC, Volk K, Kuo MS, Gordillo R, Kharitonenkov A, Scherer PE. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab 2013; 17(5): 790–797 https://doi.org/10.1016/j.cmet.2013.03.019 pmid: 23663742
37	Ge X, Chen C, Hui X, Wang Y, Lam KS, Xu A. Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem 2011; 286(40): 34533–34541 https://doi.org/10.1074/jbc.M111.248591 pmid: 21846717
38	Copple BL, Li T. Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol Res 2016; 104: 9–21 https://doi.org/10.1016/j.phrs.2015.12.007 pmid: 26706784
39	Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26(3): 881–885 https://doi.org/10.2337/diacare.26.3.881 pmid: 12610053
40	Sonne DP, van Nierop FS, Kulik W, Soeters MR, Vilsbøll T, Knop FK. Postprandial plasma concentrations of individual bile acids and FGF-19 in patients with type 2 diabetes. J Clin Endocrinol Metab 2016; 101(8): 3002–3009 https://doi.org/10.1210/jc.2016-1607 pmid: 27270475
41	Mueller M, Thorell A, Claudel T, Jha P, Koefeler H, Lackner C, Hoesel B, Fauler G, Stojakovic T, Einarsson C, Marschall HU, Trauner M. Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J Hepatol 2015; 62(6): 1398–1404 https://doi.org/10.1016/j.jhep.2014.12.034 pmid: 25617503
42	Goto T, Hirata M, Aoki Y, Iwase M, Takahashi H, Kim M, Li Y, Jheng HF, Nomura W, Takahashi N, Kim CS, Yu R, Seno S, Matsuda H, Aizawa-Abe M, Ebihara K, Itoh N, Kawada T. The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-α agonist-induced amelioration of metabolic disorders in obese mice. J Biol Chem 2017; 292(22): 9175–9190 https://doi.org/10.1074/jbc.M116.767590 pmid: 28404815
43	Reitman ML, Gavrilova O. A-ZIP/F-1 mice lacking white fat: a model for understanding lipoatrophic diabetes. Int J Obes Relat Metab Disord 2000; 24 (Suppl 4): S11–14 pmid: 11126232
44	Katafuchi T, Esterházy D, Lemoff A, Ding X, Sondhi V, Kliewer SA, Mirzaei H, Mangelsdorf DJ. Detection of FGF15 in plasma by stable isotope standards and capture by anti-peptide antibodies and targeted mass spectrometry. Cell Metab 2015; 21(6): 898–904 https://doi.org/10.1016/j.cmet.2015.05.004 pmid: 26039452
45	Owen BM, Ding X, Morgan DA, Coate KC, Bookout AL, Rahmouni K, Kliewer SA, Mangelsdorf DJ. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab 2014; 20(4): 670–677 https://doi.org/10.1016/j.cmet.2014.07.012 pmid: 25130400
46	Psichas A, Reimann F, Gribble FM. Gut chemosensing mechanisms. J Clin Invest 2015; 125(3): 908–917 https://doi.org/10.1172/JCI76309 pmid: 25664852
47	van Nierop FS, Scheltema MJ, Eggink HM, Pols TW, Sonne DP, Knop FK, Soeters MR. Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol 2017; 5(3): 224–233 https://doi.org/10.1016/S2213-8587(16)30155-3 pmid: 27639537
48	Hauge M, Ekberg JP, Engelstoft MS, Timshel P, Madsen AN, Schwartz TW. Gq and Gs signaling acting in synergy to control GLP-1 secretion. Mol Cell Endocrinol 2017; 449: 64–73 pmid: 27908836
49	Vettorazzi JF, Ribeiro RA, Borck PC, Branco RC, Soriano S, Merino B, Boschero AC, Nadal A, Quesada I, Carneiro EM. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic β cells. Metabolism 2016; 65(3): 54–63 https://doi.org/10.1016/j.metabol.2015.10.021 pmid: 26892516
50	Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10(3): 167–177 https://doi.org/10.1016/j.cmet.2009.08.001 pmid: 19723493
51	Miyamoto J, Hasegawa S, Kasubuchi M, Ichimura A, Nakajima A, Kimura I. Nutritional signaling via free fatty acid receptors. Int J Mol Sci 2016; 17(4): 450 https://doi.org/10.3390/ijms17040450 pmid: 27023530
52	Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab 2013; 15(1): 15–27 https://doi.org/10.1111/j.1463-1326.2012.01663.x pmid: 22776039
53	Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99(3): 257–273 https://doi.org/10.1097/01.smj.0000208120.73327.db pmid: 16553100
54	Sonne DP, Hansen M, Knop FK. Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. Eur J Endocrinol 2014; 171(2): R47–R65 https://doi.org/10.1530/EJE-14-0154 pmid: 24760535
55	Potthoff MJ, Potts A, He T, Duarte JA, Taussig R, Mangelsdorf DJ, Kliewer SA, Burgess SC. Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice. Am J Physiol Gastrointest Liver Physiol 2013; 304(4): G371–G380 https://doi.org/10.1152/ajpgi.00400.2012 pmid: 23257920
56	Harach T, Pols TW, Nomura M, Maida A, Watanabe M, Auwerx J, Schoonjans K. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2012; 2(1): 430 https://doi.org/10.1038/srep00430 pmid: 22666533
57	Mazidi M, Rezaie P, Karimi E, Kengne AP. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 2017; 227: 850–857 https://doi.org/10.1016/j.ijcard.2016.10.011 pmid: 28029410
58	Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsbøll T, Knop FK. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials. J Diabetes Complications 2017; 31(5): 918–927 https://doi.org/10.1016/j.jdiacomp.2017.01.011 pmid: 28238556
59	Chen L, Yao X, Young A, McNulty J, Anderson D, Liu Y, Nystrom C, Croom D, Ross S, Collins J, Rajpal D, Hamlet K, Smith C, Gedulin B. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab 2012; 302(1): E68–E76 https://doi.org/10.1152/ajpendo.00323.2011 pmid: 21934041
60	Ferrebee CB, Dawson PA. Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids. Acta Pharm Sin B 2015; 5(2): 129–134 https://doi.org/10.1016/j.apsb.2015.01.001 pmid: 26579438
61	McGavigan AK, Garibay D, Henseler ZM, Chen J, Bettaieb A, Haj FG, Ley RE, Chouinard ML, Cummings BP. TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice. Gut 2017; 66(2): 226–234 https://doi.org/10.1136/gutjnl-2015-309871 pmid: 26511794
62	Haeusler RA, Astiarraga B, Camastra S, Accili D, Ferrannini E. Human insulin resistance is associated with increased plasma levels of 12α-hydroxylated bile acids. Diabetes 2013; 62(12): 4184–4191 https://doi.org/10.2337/db13-0639 pmid: 23884887
63	Manoogian ENC, Panda S. Circadian rhythms, time-restricted feeding, and healthy aging. Ageing Res Rev 2017; 39: 59–67 https://doi.org/10.1016/j.arr.2016.12.006 pmid: 28017879
64	Froy O. Circadian aspects of energy metabolism and aging. Ageing Res Rev 2013; 12(4): 931–940 https://doi.org/10.1016/j.arr.2013.09.002 pmid: 24075855
65	Adamovich Y, Rousso-Noori L, Zwighaft Z, Neufeld-Cohen A, Golik M, Kraut-Cohen J, Wang M, Han X, Asher G. Circadian clocks and feeding time regulate the oscillations and levels of hepatic triglycerides. Cell Metab 2014; 19(2): 319–330 https://doi.org/10.1016/j.cmet.2013.12.016 pmid: 24506873
66	Kalsbeek A, la Fleur S, Fliers E. Circadian control of glucose metabolism. Mol Metab 2014; 3(4): 372–383 https://doi.org/10.1016/j.molmet.2014.03.002 pmid: 24944897
67	Ribas-Latre A, Eckel-Mahan K. Interdependence of nutrient metabolism and the circadian clock system: importance for metabolic health. Mol Metab 2016; 5(3): 133–152 https://doi.org/10.1016/j.molmet.2015.12.006 pmid: 26977390
68	Le Martelot G, Claudel T, Gatfield D, Schaad O, Kornmann B, Lo Sasso G, Moschetta A, Schibler U. REV-ERBα participates in circadian SREBP signaling and bile acid homeostasis. PLoS Biol 2009; 7(9): e1000181 https://doi.org/10.1371/journal.pbio.1000181 pmid: 19721697
69	Pathak P, Li T, Chiang JY. Retinoic acid-related orphan receptor α regulates diurnal rhythm and fasting induction of sterol 12α-hydroxylase in bile acid synthesis. J Biol Chem 2013; 288(52): 37154–37165 https://doi.org/10.1074/jbc.M113.485987 pmid: 24226095
70	Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science 2010; 330(6009): 1349–1354 https://doi.org/10.1126/science.1195027 pmid: 21127246
71	Wada E, Koyanagi S, Kusunose N, Akamine T, Masui H, Hashimoto H, Matsunaga N, Ohdo S. Modulation of peroxisome proliferator-activated receptor-α activity by bile acids causes circadian changes in the intestinal expression of Octn1/Slc22a4 in mice. Mol Pharmacol 2015; 87(2): 314–322 https://doi.org/10.1124/mol.114.094979 pmid: 25422143
72	Ferrell JM, Chiang JY. Short-term circadian disruption impairs bile acid and lipid homeostasis in mice. Cell Mol Gastroenterol Hepatol 2015; 1(6):664–677 https://doi.org/DOI: 10.1016/j.jcmgh.2015.08.003 pmid: 26645046
73	Lis CG, Grutsch JF, Wood P, You M, Rich I, Hrushesky WJ. Circadian timing in cancer treatment: the biological foundation for an integrative approach. Integr Cancer Ther 2003; 2(2): 105–111 https://doi.org/10.1177/1534735403002002002 pmid: 15035897
74	Zhang YK, Yeager RL, Klaassen CD. Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab Dispos 2009; 37(1): 106–115 https://doi.org/10.1124/dmd.108.024174 pmid: 18838502
75	Sinal CJ, Yoon M, Gonzalez FJ. Antagonism of the actions of peroxisome proliferator-activated receptor-α by bile acids. J Biol Chem 2001; 276(50): 47154–47162 https://doi.org/10.1074/jbc.M107000200 pmid: 11606578

Viewed

Full text

Abstract

Cited

Shared

Discussed